The Company reports about growth in sales of antibiotics and respiratory drugs

Tchaikapharma High Quality Medicines Inc. reports revenue growth and profit more than doubling by the end of 2021.  The company’s net profit at the end of the last quarter for 2021 amounted to BGN 1,667 million compared to BGN 604 thousand at the end of 2020, an increase of 176%.

The strongest growth in 2021 was reported in sales of antibiotics and respiratory medicines, given the prevalence of COVID-19, to BGN 7,325 million compared to BGN 4,42 million in the previous year, or by 65,72% (BGN 2,9 million). There was also growth in sales of the company’s drugs for the nervous system, as well as for the digestive system and metabolism, oncology and musculoskeletal system and connective tissue.

In the last year, Tchaikapharma’s shares rose by 9.5% and its market capitalisation reached BGN 1.1 billion.

The full article is available here in Bulgarian.